ReviewIndian journal of ophthalmology2026
Emerging role of stem cells and tissue engineering in oculoplastic surgery.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancements in stem-cell biology and tissue engineering (TE) are transforming the field of oculoplastic surgery by offering innovative solutions for eyelid, orbital, and periocular reconstruction. Stem cells, including mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and adipose-derived stem cells (ASCs), provide regenerative potential through their ability to differentiate into ocular adnexal tissues and modulate wound healing via paracrine effects. Tissue-engineered constructs, combining biocompatible scaffolds, cellular components, and growth factors, enable the development of functional replacements for eyelid skin, tarsus, conjunctiva, and lacrimal structures. These technologies enhance esthetic and functional outcomes, reduce donor-site morbidity, and may overcome limitations of traditional grafts and flaps. Current applications include periocular volume augmentation, eyelid reconstruction, and management of anophthalmic sockets, with ongoing research directed toward bioengineered lacrimal glands and dynamic eyelid substitutes. Although challenges remain, such as optimizing scaffold integration, vascularization, and long-term safety, stem-cell and TE approaches hold significant promise for personalized, restorative, and regenerative strategies in oculoplastic surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.